Latest Posts › Decriminalization of Marijuana

Share:

Re-scheduling in Limbo – Hearing Cancelled

Drug Enforcement Administration (DEA) Administrative Law Judge (ALJ) John Mulrooney has cancelled the long-awaited cannabis re-scheduling hearing set for next week. Pro-reform advocates have suggested that the DEA had...more

Breaking News: DEA To Reschedule Cannabis

Cannabis would move to Schedule III from Schedule I under this reclassification. In a move long awaited by the cannabis industry, the Drug Enforcement Administration (DEA) has decided to re-schedule cannabis. Currently...more

Cannabis Receives a Welcome Push from The Alcoholic Beverage Industry, Leaving Regulators Buzzing

The Blunt Truth® has long covered the intersection of alcohol and cannabis. For example, just last month we explored the potential for regulatory confusion that might ensue if states begin allowing the sale of cannabis in...more

In Case You Missed It: Key Marijuana Law Developments in 2022

It has already been a busy year for marijuana law! Catch up on key legislative, regulatory, and legal developments affecting the manufacture, distribution, sale, and use of marijuana occurring in 2022, including key decisions...more

The Buzz at CannaVest West

Happy New Year and welcome back as The Blunt Truth begins its seventh year of publication. ...more

Will Banks be Able to Play it SAFE with Marijuana Related Businesses?

Marijuana is estimated to be a $10 billion industry and rapidly growing. Almost all of it is conducted in cash. Although legal in thirty three states plus Washington, D.C., Puerto Rico and Guam, marijuana remains illegal at...more

FDA Approves First Marijuana-Based Drug To Treat Epilepsy

On June 25, 2018, the Food and Drug Administration (“FDA”) approved Epidiolex (cannabidiol), the first marijuana derived drug for use in the United States, to treat two rare forms of epilepsy....more

8 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide